← Back to Screener
Profound Medical Corp. Common Stock (PROF)
Price$6.66
Value ScoreD
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-5.06%
Price vs S&P 500 (4W)-0.84%
VGM Score55.84
Market Capitalization$343.75M
All Metrics
Book Value / Share (Quarterly)$1.64
P/TBV (Annual)3.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)34.06%
Cash Flow / Share (Quarterly)$-1.07
Price vs S&P 500 (YTD)-20.63%
Gross Margin (TTM)71.07%
Net Profit Margin (TTM)-206.76%
EPS (TTM)$-1.25
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-1.25
Revenue Growth (5Y)17.12%
EPS (Annual)$-1.41
ROI (Annual)-60.01%
Gross Margin (Annual)70.77%
Net Profit Margin (5Y Avg)-359.50%
Cash / Share (Quarterly)$1.38
Revenue Growth QoQ (YoY)103.62%
ROA (Last FY)-54.95%
Revenue Growth TTM (YoY)58.59%
EBITD / Share (TTM)$-1.19
ROE (5Y Avg)-58.99%
Operating Margin (TTM)-202.56%
Cash Flow / Share (Annual)$-1.06
P/B Ratio4.15x
P/B Ratio (Quarterly)3.90x
Net Income / Employee (Annual)$-325,000
EV / Revenue (TTM)10.68x
Net Interest Coverage (TTM)-38.77x
ROA (TTM)-64.06%
EPS Incl Extra (Annual)$-1.41
Current Ratio (Annual)12.52x
Quick Ratio (Quarterly)5.63x
3-Month Avg Trading Volume0.02M
52-Week Price Return22.73%
Revenue / Employee (TTM)$143,600
Tangible BV / Share (Quarterly)$1.63
P/S Ratio (Annual)15.32x
Asset Turnover (Annual)0.21x
52-Week High$12.40
Operating Margin (5Y Avg)-376.98%
EPS Excl Extra (Annual)$-1.41
CapEx CAGR (5Y)-7.11%
Tangible BV CAGR (5Y)-7.03%
26-Week Price Return2.86%
Quick Ratio (Annual)11.02x
13-Week Price Return-6.60%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)6.56x
Enterprise Value$200.91M
Revenue / Share Growth (5Y)4.75%
Asset Turnover (TTM)0.31x
Book Value / Share Growth (5Y)-17.59%
Revenue / Employee (Annual)$122,900
Inventory Turnover (Annual)0.67x
Pretax Margin (Annual)-262.88%
Cash / Share (Annual)$1.65
3-Month Return Std Dev85.83%
Gross Margin (5Y Avg)57.14%
Net Income / Employee (TTM)$-296,900
ROE (Last FY)-64.08%
Net Interest Coverage (Annual)-8.13x
EPS Basic Excl Extra (Annual)$-1.41
Receivables Turnover (TTM)2.56x
Total Debt / Equity (Quarterly)0.08x
EPS Incl Extra (TTM)$-1.25
Receivables Turnover (Annual)2.36x
ROI (TTM)-72.30%
P/S Ratio (TTM)13.11x
Pretax Margin (5Y Avg)-358.38%
Revenue / Share (Annual)$0.53
Tangible BV / Share (Annual)$1.83
Price vs S&P 500 (52W)-1.63%
Year-to-Date Return-13.28%
5-Day Price Return-0.11%
EPS Normalized (Annual)$-1.41
ROA (5Y Avg)-47.90%
Net Profit Margin (Annual)-264.44%
Month-to-Date Return-1.99%
Cash Flow / Share (TTM)$-1.82
EBITD / Share (Annual)$-1.35
Operating Margin (Annual)-256.27%
LT Debt / Equity (Annual)0.07x
ROI (5Y Avg)-52.16%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.25
P/TBV (Quarterly)3.91x
P/B Ratio (Annual)3.23x
Inventory Turnover (TTM)0.69x
Pretax Margin (TTM)-205.51%
Book Value / Share (Annual)$1.83
Price vs S&P 500 (13W)-14.85%
Beta2.04x
Revenue / Share (TTM)$0.52
ROE (TTM)-78.88%
52-Week Low$5.23
vGradeD
gGradeA
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PROFProfound Medical Corp. Common Stock | D | A | C | $6.66 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Profound Medical develops minimally invasive, image-guided ablation systems for treating prostate disease. Its flagship TULSA-PRO system combines real-time MRI guidance with robotic ultrasound technology to precisely ablate prostate tissue without surgical incisions. The system integrates with hospitals' existing MRI infrastructure, requiring only disposable devices and durable equipment.